Analysis of Chlamydia trachomalis serovar distribution changes in the Netherlands (1986-2002) [1]

Sexually Transmitted Infections

Volumn 80, Issue 2, 2004, Pages 151-152

  Spaargaren, J ^a   Verhaest, I ^a   Mooij, S ^a   Smit, C ^a   Fennema, H S A ^a   Coutinho, R A ^a   Salvador Pena A ^b   Morre S A ^b  

^a MUNICIPAL HEALTH SERVICE   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; EPIDEMIOLOGICAL DATA; GEOGRAPHIC DISTRIBUTION; HUMAN; LETTER; NETHERLANDS; NONHUMAN; PRIORITY JOURNAL; SEROTYPE; SEXUALLY TRANSMITTED DISEASE; CLASSIFICATION; COHORT ANALYSIS; FEMALE; GENETICS; GENOTYPE; MALE; MICROBIOLOGY; SEROTYPING;

CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; COHORT STUDIES; FEMALE; GENOTYPE; HUMANS; MALE; NETHERLANDS; SEROTYPING;

EID: 1942521798     PISSN: 13684973     EISSN: None     Source Type: Journal    
DOI: 10.1136/sti.2003.006395     Document Type: Letter

References (14)

1. Morré SA, Ossewaarde JM, Lan J, et al. Serotyping and genotyping of genital Chlamydia trachomatis isolates reveal variants of serovars Ba, G, and J as confirmed by omp1 nucleotide sequence analysis. J Clin Microbiol 1998;36:345-51.
2. Dean D, Miller K. Molecular and mutation trend analysis of omp1 alleles for serovar E of Chlamydia trachomatis. Implications for the immunopathogenesis of disease. J Clin Invest 1997;99:475-83.
3. Gerbase A, Rowley J, Heymann D, et al. Global prevalence and incidence estimates of selected curable STDs. Sex Transm Infect 1998;74:S12-S14.
4. Morré SA, Welte R, Postma MJ. Major improvements in cost effectiveness of screening women for Chlamydia trachomatis using pooled urine specimens and high performance testing. Sex Transm Infect 2002;78:74-5.
5. Postma MJ, Welte R, van den Hoek JA, et al. Comparing cost effectiveness of screening women for Chlamydia trachomatis in systematic and opportunistic approaches. Sex Transm Infect 2002;78:73-4.
6. Anttila T, Saikku P, Koskela P, et al. Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. JAMA 2001;285:47-51.
7. Wagenvoort JHT, Suchland RJ, Stamm WE. Serovar distribution of urogenital Chlamydia trachomatis strains in the Netherlands. Genitourin Med 1988;64:159-61.
8. Van de Laar MJ, Lan J, van Duynhoven YT, et al. Differences in clinical manifestations of genital chlamydial infections related to serovars. Genitourin Med 1996;72:261-5.
9. Morre SA, Ossewaarde JM, Lan J, et al. Serotyping and genotyping of genital Chlamydia trachomatis isolates reveal variants of serovars Ba, G, and J as confirmed by omp1 nucleotide sequence analysis. J Clin Microbiol 1998;36:345-51.
10. Ossewaarde JM, Rieffe M, de Vries A, et al. Comparison of two panels of monoclonal antibodies for determination of Chlamydia trochomatis serovars. J Clin Microbiol 1994;32:2968-74.
11. Lan J, Melgers I, Meijer CJLM, et al. Prevalence and serovar distribution of asymptomatic cervical Chlamydia trachomatis infections as determined by highly sensitive PCR. J Clin Microbiol 1995;33:3194-7.
12. Van Duynhoven YT, Ossewaarde JM, Derksen-Nawrocki RP, et al. Chlamydia trachomatis genotypes: correlation with clinical manifestations of infection and patients' characteristics. Clin Infect Dis 1997;26:314-22.
13. Morre SA, Rozendaal L, van Valkengoed IGM, et al. Urogenital Chlamydia trachomatis serovars in men and women with symtomatic and asymptomatic infection: an association with clinical manifestations? J Clin Microbiol 2000;38:2292-6.
14. Morre SA. Chlamydia trachomatis infections in the human urogenital tract. Thesis. 1999;chapter 9.